-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-508997-27-00
6
2024-10-14
Need for a subpectoral implantation of cardiac implantable electronic
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-506613-22-00
5
2024-09-25
coronary artery disease
-
2024-511419-22-00
10
2024-09-03
Hormone receptor positive/HER2 negative, triple-negative or HER2 posit
-
2023-506617-21-00
5
2024-08-29
Major depressive disorder
-
2023-504169-22-02
5
2024-07-31
Severe cardiac inflammation
-
2023-507684-19-00
5
2024-07-24
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
-
2022-502135-19-00
4
2024-07-18
Calcific Aortic Valve Stenosis
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2022-502559-69-01
4
2024-07-04
advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classifi
-
2022-500210-26-00
5
2024-06-28
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
2023-508158-24-00
4
2024-06-25
Moderately to Severely Active Crohn’s Disease
-
2023-506150-21-00
4
2024-05-29
Celiac Disease
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2022-501119-14-01
4
2024-04-16
Ulcerative Colitis
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-504472-24-00
4
2024-03-19
Early Idiopathic Parkinson’s disease (PD)
-
2023-505267-36-00
5
2024-03-15
Glioblastoma
-
2022-502282-24-00
5
2024-02-14
Primary generalized tonic-clonic seizures
-
2022-500531-36-00
4
2024-02-02
Type 1 diabetes mellitus
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma